Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide with Docetaxel in mCRPC (Mainsail)
NCT00988208Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Nov 2009
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 21
01
Overview
A Phase 3 trial of lenalidomide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Celgene Corporation. Started Nov 2009; status: completed.
02
Drugs
lenalidomide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00988208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00988208.